Loading clinical trials...
Loading clinical trials...
A PHASE 1B OPEN-LABEL THREE-ARM MULTI-CENTER STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF PF-05212384 (PI3K/MTOR INHIBITOR) IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS
Conditions
Interventions
PF-05212384 (gedatolisib)
Docetaxel
+2 more
Locations
29
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Ronald Reagan UCLA Medical Center
Los Angeles, California, United States
UCLA Hematology Oncology
Los Angeles, California, United States
Westwood Bowyer Clinic
Los Angeles, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Start Date
September 10, 2013
Primary Completion Date
January 8, 2020
Completion Date
January 8, 2020
Last Updated
September 13, 2022
NCT06126276
NCT04550494
NCT05372640
NCT07213804
NCT04704661
NCT07209111
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions